- Home
- ACCL vs KALA Comparison
ACCL vs KALA Comparison
Compare ACCL & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCL
- KALA
- Stock Information
- Founded
- ACCL 2009
- KALA 2009
- Country
- ACCL Hong Kong
- KALA United States
- Employees
- ACCL N/A
- KALA N/A
- Industry
- ACCL Professional Services
- KALA Biotechnology: Pharmaceutical Preparations
- Sector
- ACCL Consumer Discretionary
- KALA Health Care
- Exchange
- ACCL Nasdaq
- KALA Nasdaq
- Market Cap
- ACCL 32.1M
- KALA 26.2M
- IPO Year
- ACCL 2025
- KALA 2017
- Fundamental
- Price
- ACCL $2.96
- KALA $0.80
- Analyst Decision
- ACCL
- KALA Buy
- Analyst Count
- ACCL 0
- KALA 3
- Target Price
- ACCL N/A
- KALA $31.50
- AVG Volume (30 Days)
- ACCL 440.5K
- KALA 875.4K
- Earning Date
- ACCL 11-20-2025
- KALA 11-07-2025
- Dividend Yield
- ACCL N/A
- KALA N/A
- EPS Growth
- ACCL N/A
- KALA N/A
- EPS
- ACCL 0.09
- KALA N/A
- Revenue
- ACCL $4,874,058.00
- KALA N/A
- Revenue This Year
- ACCL N/A
- KALA N/A
- Revenue Next Year
- ACCL N/A
- KALA N/A
- P/E Ratio
- ACCL $33.28
- KALA N/A
- Revenue Growth
- ACCL 17.95
- KALA N/A
- 52 Week Low
- ACCL $2.10
- KALA $0.77
- 52 Week High
- ACCL $4.45
- KALA $20.60
- Technical
- Relative Strength Index (RSI)
- ACCL N/A
- KALA 26.34
- Support Level
- ACCL N/A
- KALA $0.77
- Resistance Level
- ACCL N/A
- KALA $0.83
- Average True Range (ATR)
- ACCL 0.00
- KALA 0.10
- MACD
- ACCL 0.00
- KALA 0.35
- Stochastic Oscillator
- ACCL 0.00
- KALA 3.31
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.